The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond

For almost two decades, pioglitazone has been prescribed primarily to prevent and treat insulin resistance in some type 2 diabetic patients. In this review, we trace the path to discovery of pioglitazone as a thiazolidinedione compound, the glitazone tracks through the regulatory agencies, the trek...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Frontiers in Pharmacology
المؤلفون الرئيسيون: Pallavi R. Devchand, Tianyun Liu, Russ B. Altman, Garret A. FitzGerald, Eric E. Schadt
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Frontiers Media S.A. 2018-10-01
الموضوعات:
pioglitazone
PPAR gamma
protein–drug interactions
nuclear receptor
glitazone medications
الوصول للمادة أونلاين:https://www.frontiersin.org/article/10.3389/fphar.2018.01093/full

الانترنت

https://www.frontiersin.org/article/10.3389/fphar.2018.01093/full

مواد مشابهة